pfizer inc pfe shares are trading higher monday in the wake of a newly released study suggesting the companys oral weight loss drug may be as effective as novo nordisks nvo ozempic injection what happened according to a peerreviewed study of phase 2 clinical trial results published on the jama network pfizers danuglipron works quicker than and results in a similar amount of weight loss as ozempic the results were initially presented at a medical conference toward the end of 2022 but they were not compared to novo nordisks injection at that time the study shows that 411 randomized participants with type 2 diabetes were given either pfizers oral drug or a placebo twice a day for 16 weeks the doubleblind treatment period was completed by 316 participants all danuglipron groups demonstrated statistically significant doseresponsive declines from baseline in hba at week 16 compared with placebo the study says check this out medtronics ev icd system proves effective in cardiac arrhythmia management longterm study results the results from the study are significant because they show that danuglipron is likely as effective as ozempic for weight loss but offers the advantage of being orally administered instead of injectionbased the study concludes that the phase 2b trial demonstrated glycemic and body weight efficacy in a range of doses during a short but clinically relevant time frame why it matters entrepreneur and author of laughing at wall street chris camillo doesnt believe the results pose any substantive risk to competitors novo nordisk and eli lilly and co lly novos oral semaglutide medication rybelsus is already in market and is on the cusp of seeking approval for an enhanced dosage formulation potentially facilitating weight reduction of up to 20 pounds camillo said furthermore both novo and eli lilly have nextgeneration injectable glp1 medications in pipeline that are indicating transformative improvements with anticipated weight loss up to an astounding 27 of body weight obesity is common and costly according to the cdc us obesity prevalence was 419 from 2017 to 2020 see also fda votes in favor of pfizers maternal rsv vaccine to prevent disease in infants pfe price action pfizer shares were up 415 at 3830 at the time of publication according to benzinga pro